Posted: 5 February 2025
Optiscan has been featured in Stockhead, The Australian, and 11 News Corp mastheads following the announcement of its pre-clinical gastrointestinal (GI) study in Germany.
The piece explores how Optiscan’s first flexible GI imaging prototype is designed to provide real-time, high-resolution imaging of the gastrointestinal tract, potentially transforming the early detection and diagnosis of GI diseases, including colorectal cancer.
The study, led by world-renowned gastroenterologist Professor Ralph Kiesslich, is being conducted in collaboration with the University Medical Center Mainz and will assess the capabilities of Optiscan’s Gen2 confocal imaging system.
The article also highlights Optiscan’s broader push into AI-driven imaging, with research efforts focused on integrating artificial intelligence to enhance diagnostic accuracy and clinical decision-making.
Commenting on this development, Optiscan CEO Dr. Camile Farah stated: “GI diseases represent a significant global health challenge, affecting millions of lives each year. Early detection and precise intervention are critical, yet traditional diagnostic tools often fall short in providing timely and accurate insights.”
